메뉴 건너뛰기




Volumn 16, Issue 9, 2014, Pages 812-818

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

Author keywords

DPP 4 inhibition; Glucagon; Hypoglycaemia; Insulin treated; Type 2 diabetes; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PLACEBO; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; NITRILE; PYRROLIDINE DERIVATIVE;

EID: 84905725690     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12284     Document Type: Article
Times cited : (43)

References (34)
  • 1
    • 24944577486 scopus 로고    scopus 로고
    • Alpha cell function in health and disease: influence of glucagon-like peptide-1
    • Dunning BE, Foley JE, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005; 48: 1700-1713.
    • (2005) Diabetologia , vol.48 , pp. 1700-1713
    • Dunning, B.E.1    Foley, J.E.2    Ahrén, B.3
  • 2
    • 0141446228 scopus 로고    scopus 로고
    • Enhancing incretin action for the treatment of type 2 diabetes
    • Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
    • (2003) Diabetes Care , vol.26 , pp. 2929-2940
    • Drucker, D.J.1
  • 3
    • 84870054636 scopus 로고    scopus 로고
    • GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
    • Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012; 8: 728-742.
    • (2012) Nat Rev Endocrinol , vol.8 , pp. 728-742
    • Meier, J.J.1
  • 4
    • 84874367468 scopus 로고    scopus 로고
    • Incretin therapy of type 2 diabetes. GLP-1 receptor agonists and DPP-4 inhibitors
    • Ahrén B. Incretin therapy of type 2 diabetes. GLP-1 receptor agonists and DPP-4 inhibitors. J Eur Diabet Nursing 2013; 10: 31-36.
    • (2013) J Eur Diabet Nursing , vol.10 , pp. 31-36
    • Ahrén, B.1
  • 5
    • 84859341109 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors: 3 years of experience
    • Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 2012; 14: 350-364.
    • (2012) Diabetes Technol Ther , vol.14 , pp. 350-364
    • Derosa, G.1    Maffioli, P.2
  • 6
    • 0021263283 scopus 로고
    • Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions
    • Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest 1984; 73: 1532-1541.
    • (1984) J Clin Invest , vol.73 , pp. 1532-1541
    • Bolli, G.B.1    Tsalikian, E.2    Haymond, M.W.3    Cryer, P.E.4    Gerich, J.E.5
  • 7
    • 84857401843 scopus 로고    scopus 로고
    • Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes
    • Cryer BE. Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012; 153: 1039-1048.
    • (2012) Endocrinology , vol.153 , pp. 1039-1048
    • Cryer, B.E.1
  • 8
    • 65249095686 scopus 로고    scopus 로고
    • Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes
    • Ahrén B, Schweizer A, Dejager S et al. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 2009; 94: 1236-1243.
    • (2009) J Clin Endocrinol Metab , vol.94 , pp. 1236-1243
    • Ahrén, B.1    Schweizer, A.2    Dejager, S.3
  • 9
    • 34548118796 scopus 로고    scopus 로고
    • Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes
    • Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA1c over one year in drug-naive patients with type 2 diabetes. Diabet Med 2007; 24: 955-961.
    • (2007) Diabet Med , vol.24 , pp. 955-961
    • Schweizer, A.1    Couturier, A.2    Foley, J.E.3    Dejager, S.4
  • 10
    • 34147093268 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    • Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
    • (2007) Diabetes Care , vol.30 , pp. 890-895
    • Bosi, E.1    Camisasca, R.P.2    Collober, C.3    Rochotte, E.4    Garber, A.J.5
  • 11
    • 58149330590 scopus 로고    scopus 로고
    • Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
    • Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009; 11: 157-166.
    • (2009) Diabetes Obes Metab , vol.11 , pp. 157-166
    • Ferrannini, E.1    Fonseca, V.2    Zinman, B.3
  • 12
    • 33846828660 scopus 로고    scopus 로고
    • Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo controlled study
    • Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo controlled study. Diabetes Obes Metab 2007; 9: 166-174.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 166-174
    • Garber, A.J.1    Schweizer, A.2    Baron, M.A.3    Rochotte, E.4    Dejager, S.5
  • 13
    • 54249106294 scopus 로고    scopus 로고
    • Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
    • Garber AJ, Foley JE, Banerji MA et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008; 10: 1047-1056.
    • (2008) Diabetes Obes Metab , vol.10 , pp. 1047-1056
    • Garber, A.J.1    Foley, J.E.2    Banerji, M.A.3
  • 14
    • 4744363623 scopus 로고    scopus 로고
    • Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients type 1 and insulin-treated type 2 diabetes mellitus
    • Holstein A, Hammer C, Plachke A et al. Hormonal counterregulation during severe hypoglycaemia under everyday conditions in patients type 1 and insulin-treated type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004; 112: 429-434.
    • (2004) Exp Clin Endocrinol Diabetes , vol.112 , pp. 429-434
    • Holstein, A.1    Hammer, C.2    Plachke, A.3
  • 15
    • 84877633796 scopus 로고    scopus 로고
    • Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
    • Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature. Diabetes Obes Metab 2013; 15: 485-502.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 485-502
    • Balena, R.1    Hensley, I.E.2    Miller, S.3    Barnett, A.H.4
  • 16
    • 84879186130 scopus 로고    scopus 로고
    • Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin
    • Schweizer A, Foley JE, Kothny W, Ahrén B. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. Vasc Health Risk Manag 2013; 9: 57-64.
    • (2013) Vasc Health Risk Manag , vol.9 , pp. 57-64
    • Schweizer, A.1    Foley, J.E.2    Kothny, W.3    Ahrén, B.4
  • 17
    • 84873873967 scopus 로고    scopus 로고
    • Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus
    • Kothny W, Foley J, Kozlovski P, Shao O, Gallwitz B, Lukashevich V. Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 252-257.
    • (2013) Diabetes Obes Metab , vol.15 , pp. 252-257
    • Kothny, W.1    Foley, J.2    Kozlovski, P.3    Shao, O.4    Gallwitz, B.5    Lukashevich, V.6
  • 18
  • 19
    • 84873848407 scopus 로고    scopus 로고
    • Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
    • Lukashevich V, Schweizer A, Foley JE, Fickinson S, Groop PH, Kothny W. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment. Vasc Health Risk Manag 2013; 9: 21-28.
    • (2013) Vasc Health Risk Manag , vol.9 , pp. 21-28
    • Lukashevich, V.1    Schweizer, A.2    Foley, J.E.3    Fickinson, S.4    Groop, P.H.5    Kothny, W.6
  • 20
    • 84882932426 scopus 로고    scopus 로고
    • Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
    • Ahrén B. Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013; 9: 155-163.
    • (2013) Vasc Health Risk Manag , vol.9 , pp. 155-163
    • Ahrén, B.1
  • 21
    • 84867238377 scopus 로고    scopus 로고
    • Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes
    • Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab 2012; 97: 3799-3806.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 3799-3806
    • Farngren, J.1    Persson, M.2    Schweizer, A.3    Foley, J.E.4    Ahrén, B.5
  • 22
    • 23844463766 scopus 로고    scopus 로고
    • Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes
    • Mari A, Sallas WM, He YL et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 4888-4894.
    • (2005) J Clin Endocrinol Metab , vol.90 , pp. 4888-4894
    • Mari, A.1    Sallas, W.M.2    He, Y.L.3
  • 23
    • 2442482515 scopus 로고    scopus 로고
    • Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes
    • Ahrén B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2078-2084
    • Ahrén, B.1    Landin-Olsson, M.2    Jansson, P.A.3    Svensson, M.4    Holmes, D.5    Schweizer, A.6
  • 24
    • 79961191559 scopus 로고    scopus 로고
    • Regulation of glucagon secretion by incretins
    • Holst JJ, Christensen M, Lund A et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011; 13(Suppl. 1): 89-94.
    • (2011) Diabetes Obes Metab , vol.13 , Issue.SUPPL. 1 , pp. 89-94
    • Holst, J.J.1    Christensen, M.2    Lund, A.3
  • 25
    • 55649108863 scopus 로고    scopus 로고
    • Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pâncreas
    • de Heer J, Rasmussen C, Coy D, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pâncreas. Diabetologia 2008; 51: 2263-2270.
    • (2008) Diabetologia , vol.51 , pp. 2263-2270
    • de Heer, J.1    Rasmussen, C.2    Coy, D.3    Holst, J.J.4
  • 26
    • 56049086867 scopus 로고    scopus 로고
    • Insulin as a physiological modulator of glucagon secretion
    • Bansal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol 2008; 295: E751-E761.
    • (2008) Am J Physiol , vol.295
    • Bansal, P.1    Wang, Q.2
  • 27
    • 0036959991 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemia clamp experiments in healthy volunteers
    • Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemia clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87: 1239-1246.
    • (2002) J Clin Endocrinol Metab , vol.87 , pp. 1239-1246
    • Nauck, M.A.1    Heimesaat, M.M.2    Behle, K.3
  • 28
    • 82255185915 scopus 로고    scopus 로고
    • Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
    • Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011; 60: 103-109.
    • (2011) Diabetes , vol.60 , pp. 103-109
    • Christensen, M.1    Vedtofte, L.2    Holst, J.J.3    Vilsbøll, T.4    Knop, F.K.5
  • 29
    • 0030936890 scopus 로고    scopus 로고
    • Activation of autonomic nervous and the adrenal medula contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women
    • Havel PJ, Ahrén B. Activation of autonomic nervous and the adrenal medula contributes to increased glucagon secretion during moderate insulin-induced hypoglycemia in women. Diabetes 1997; 46: 801-807.
    • (1997) Diabetes , vol.46 , pp. 801-807
    • Havel, P.J.1    Ahrén, B.2
  • 30
    • 84857401071 scopus 로고    scopus 로고
    • Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia
    • Taborsky GJ Jr, Mundinger TO. Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012; 153: 1055-1062.
    • (2012) Endocrinology , vol.153 , pp. 1055-1062
    • Taborsky Jr., G.J.1    Mundinger, T.O.2
  • 31
    • 0017948650 scopus 로고
    • Vagal, cholinergic regulation of pancreatic polypeptide secretion
    • Schwartz TW, Holst JJ, Fahrenkrug J et al. Vagal, cholinergic regulation of pancreatic polypeptide secretion. J Clin Invest 1978; 61: 781-789.
    • (1978) J Clin Invest , vol.61 , pp. 781-789
    • Schwartz, T.W.1    Holst, J.J.2    Fahrenkrug, J.3
  • 32
    • 0030971354 scopus 로고    scopus 로고
    • The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in meditating glucagon release in normal humans
    • Peacey SR, Rostami-Hodjegan A, George E, Tucker GT, Heller SR. The use of tolbutamide-induced hypoglycemia to examine the intraislet role of insulin in meditating glucagon release in normal humans. J Clin Endocrinol Metab 1997; 82: 1458-1461.
    • (1997) J Clin Endocrinol Metab , vol.82 , pp. 1458-1461
    • Peacey, S.R.1    Rostami-Hodjegan, A.2    George, E.3    Tucker, G.T.4    Heller, S.R.5
  • 33
    • 0033304547 scopus 로고    scopus 로고
    • Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes
    • Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84: 3140-3146.
    • (1999) J Clin Endocrinol Metab , vol.84 , pp. 3140-3146
    • Landstedt-Hallin, L.1    Adamson, U.2    Lins, P.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.